Healthtech Solutions (OTC: HLTT) was featured in a recent article regarding its strategic appointment of CEO Edward Swanson, MD, who brings a broad array of scientific, clinical and industry specific expertise. The piece also highlighted the company’s focus to adopt a unique, portfolio-style business model. HLTT’s latest acquisition of Varian Biopharmaceuticals Inc., a precision oncology company developing novel therapeutics for the treatment of cancer, will add to its growing health care portfolio. To date, in addition to Varian Biopharmaceuticals, Healthtech Solutions is also the parent company to cloud-based ultrasound technology provider, MediScan Inc., as well as RevHeart Inc., a wholly owned subsidiary focused around treating COVID-related heart muscle injury. “I am thrilled to be joining the Healthtech team to build out a unique portfolio-style business model to bring innovative biotech and medical device technologies to the market and impact patient lives,” said Dr. Swanson. “The decentralized development of assets in this structure leverages nimble operating efficiencies at the subsidiary level combined with the experience and skillsets of the management team of Healthtech.”
To view the full article, visit https://ibn.fm/5cPVS
About Healthtech Solutions Inc.
Healthtech Solutions is a reporting public company. The board of directors is focusing the company’s resources into creating a platform to acquire and/or invest in cutting-edge health care technology in the medical device biopharma and pharmaceutical fields. The goal is to bring these solutions to market.
To date, Healthtech Solutions has invested in three areas of medical technology breakthrough:
- MediScan Inc., which is developing a technology that converts 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can provide the data equivalent to an X-ray, MRI or CT scan, without radiation and at a lower cost.
- RevHeart Inc., which is advancing critical research into the treatment of COVID-related heart muscle injury.
- Varian Biopharmaceutical Inc., a precision oncology company, is the first acquisition of Healthtech Oncology Inc.
Healthtech Solutions has a pipeline of additional acquisitions currently under due diligence.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php